Journees annuelles de diabetologie de l'Hotel-Dieu最新文献_第3页

Insulin Resistance in Type 2 Diabetes 2型糖尿病的胰岛素抵抗

Journees annuelles de diabetologie de l'Hotel-Dieu Pub Date : 2010-07-09 DOI: 10.1002/9781444324808.CH11

Hannele Yki-Järvinen

引用次数: 21

[Metformin and type 2 diabetes: the UKPDS experience]. [二甲双胍和2型糖尿病:UKPDS的经验]。

Journees annuelles de diabetologie de l'Hotel-Dieu Pub Date : 2007-01-01

X M Leverve

引用次数: 0

[Orchestration of homeostasis of glucose metabolism]. [糖代谢稳态的调节]。

Journees annuelles de diabetologie de l'Hotel-Dieu Pub Date : 2007-01-01

R N Bergman

引用次数: 0

Metformin as first choice in oral diabetes treatment: the UKPDS experience. 二甲双胍作为口服糖尿病治疗的首选:UKPDS经验。

Journees annuelles de diabetologie de l'Hotel-Dieu Pub Date : 2007-01-01

R Holman

{"title":"Metformin as first choice in oral diabetes treatment: the UKPDS experience.","authors":"R Holman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Metformin has been used successfully since the 1950s as first line pharmacotherapy to treat people with type 2 diabetes. It is a biguanide that decreases blood glucose concentration by mechanisms different from those of insulin secretagogues, such as sulphonylureas, or exogenous insulin therapy. Metformin lowers, rather than increases, fasting plasma insulin concentrations and acts by enhancing insulin sensitivity, inducing greater peripheral uptake of glucose, and decreasing hepatic glucose output. By reducing hepatic glucose output it lowers blood glucose and insulin levels with minimal risk of hypoglycaemia, and when used as monotherapy can lower HbAlc by around 1.5%. It is usually well tolerated, the most common side effects being gastrointestinal. Of particular value is that the improved glucose control seen with metformin is achieved without weight gain. Concerns that it may increase the risk of lactic acidosis have largely been allayed with recent studies suggesting less than one case per 100,000 treated patients. The UK Prospective Diabetes Study (UKPDS) demonstrated a substantial beneficial effect of metformin therapy on cardiovascular disease (CVD) outcomes, with a 36% relative risk reduction in all cause mortality and a 39% relative risk reduction in myocardial infarction . The first ever joint ADA (American Diabetes Association) and EASD (European Association for the Study of Diabetes) consensus guidelines on the management of hyperglycaemia in type 2 diabetes state explicitly that metformin should be used as first-line foundation therapy, in addition to lifestyle interventions.</p>","PeriodicalId":76064,"journal":{"name":"Journees annuelles de diabetologie de l'Hotel-Dieu","volume":" ","pages":"13-20"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27523052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Intensification of insulin therapy in type 2 diabetics]. [2型糖尿病患者胰岛素强化治疗]。

Journees annuelles de diabetologie de l'Hotel-Dieu Pub Date : 2007-01-01

J A Davidson

引用次数: 0

[Prescription, adjustment and surveillance od bolus treatment in type 1 or type 2 diabetes]. [1型或2型糖尿病的处方、调整和监测]。

Journees annuelles de diabetologie de l'Hotel-Dieu Pub Date : 2007-01-01

V J R Lassmann-Vague

引用次数: 0

Caloric restriction and longevity. 热量限制和长寿。

Journees annuelles de diabetologie de l'Hotel-Dieu Pub Date : 2007-01-01

E Ravussin, L M Redman